The role of celecoxib in the prevention of breast cancer
- سال انتشار: 1401
- محل انتشار: اولین کنگره ملی تازه های همگرایی علوم پایه و علوم پزشکی
- کد COI اختصاصی: CBSMS01_018
- زبان مقاله: انگلیسی
- تعداد مشاهده: 294
نویسندگان
چکیده
Despite decades of research, breast cancer rate continues to rise. Breast cancer remains the leading cancer-related cause of disease burden for women, involving one in ۲۰ universally.(۱) An inhibitor of cyclooxygenase ۲, Celecoxib (Cx), causes apoptosis of cancer cells(۲) In general accepted that inflammatory cells found in the tumor are contained in the neoplastic process, promoting cell proliferation, survival, and migration. Thus, administering anti inflammatory medication in cancer therapy appears to be justified A potential pathway is celecoxib and cyclooxygenase-۲ inhibition. (۳) Methods: As of ۲۰۱۹, we found ۵۸ articles in PubMed and Google Scholar databases with the keywords of breast cancer, celecoxib and prevention, and ۴۸ articles were excluded due to combining celecoxib with another drug and not being related, and we wrote review on ۱۰ of them. Results: Coombes et al testing ۲ years of adjuvant celecoxib vs placebo among ۲۶۳۹ Patients received.(celecoxib ۴۰۰ mg, or placebo once daily for ۲ years) In this randomized clinical trial, patients showed no prooves of (disease-free survival) DFS benefit for ۲ years.(۴) And Sophie Hamy et al examined a cohort of ۱۵۶ patients with human epidermal growth factor receptor ۲–negative breast cancer from the REMAGUS۰۲ and found that Celecoxib use throughout chemotherapy adversely affected survival in patients with breast cancer.(۵) But Bayraktar et al analysed that Women at increased risk for breast cancer were treated with celecoxib at ۴۰۰ mg orally twice daily for ۶ months .Celecoxib was well tolerated and induced favorable changes in serum biomarkers as well as cytology in this pilot phase II trial(۶) Also E. Harris et al found celecoxib cure (۴۰۰ mg daily for ۲ years) in a subgroup of ۶۵۵ breast cancer patients who did not receive chemotherapy decreased the hazard ratio for recurrence over ۱۰ years by ۳۵%.(۷) and Bardaweel et al have showed that celecoxib, resulted in significant antiproliferative activity against all breast cancer cell Interestingly(۸) also Misiura et al found that Cx attenuated MCF-۷ cell proliferation via arresting the cell cycle(۹) conclusion: Both preclinical and clinical studies have demonstrated promising results of the role of celecoxib in the treatment and prevention of cancer and more clinical trials are needed . It is suggested that the number of people participating in the clinical trial should be increased and a wider geographical area should be investigated And it is also suggested that more extensive studies be done in our country.کلیدواژه ها
breast cancer, celecoxib, preventionاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.